TY - JOUR
T1 - Glioblastoma in the real-world setting
T2 - patterns of care and outcome in the Austrian population
AU - Hainfellner, Andreas
AU - Borkovec, Martin
AU - Seebrecht, Lukas
AU - Neuhauser, Magdalena
AU - Roetzer-Pejrimovsky, Thomas
AU - Greutter, Lisa
AU - Surböck, Birgit
AU - Hager-Seifert, Andrea
AU - Gorka-Vom Hof, Doris
AU - Urbanic-Purkart, Tadeja
AU - Stultschnig, Martin
AU - Cijan, Clemens
AU - Würtz, Franz
AU - Calabek-Wohinz, Bernadette
AU - Pichler, Josef
AU - Höllmüller, Isolde
AU - Leibetseder, Annette
AU - Weis, Serge
AU - Kleindienst, Waltraud
AU - Seiberl, Michael
AU - Bieler, Lara
AU - Hecker, Constantin
AU - Schwartz, Christoph
AU - Iglseder, Sarah
AU - Heugenhauser, Johanna
AU - Nowosielski, Martha
AU - Thomé, Claudius
AU - Moser, Patrizia
AU - Hoffermann, Markus
AU - Loibnegger, Karin
AU - Dieckmann, Karin
AU - Tomschik, Matthias
AU - Widhalm, Georg
AU - Rössler, Karl
AU - Marosi, Christine
AU - Wöhrer, Adelheid
AU - Hainfellner, Johannes A
AU - Oberndorfer, Stefan
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/11
Y1 - 2024/11
N2 - PURPOSE: We present results of a retrospective population-based investigation of patterns of care and outcome of glioblastoma patients in Austria.PATIENTS AND METHODS: In this nation-wide cooperative project, all Austrian glioblastoma patients newly diagnosed between 2014 and 2018 and registered in the ABTR-SANOnet database were included. Histological typing used criteria of the WHO classification of CNS tumors, 4th edition 2016. Patterns of care were assessed, and all patients were followed until the end of 2019.RESULTS: 1,420 adult glioblastoma cases were identified. 813 (57.3%) patients were male and 607 (42.7%) female. Median age at diagnosis was 64 years (range: 18-88). Median overall survival (OS) was 11.6 months in the total cohort and 10.9 months in patients with proven IDH-wildtype. Median OS in the patient group ≤ 65 years receiving postoperative standard of care therapy was 16.1 months. In the patient group > 65 years with postoperative therapy, median OS was 11.2 months. Follow-up ≥ 5 years identified 13/264 (4.9%) long-term survivors. Brain tumor surgery frequently was assisted by 5-aminolevulinic acid (5-ALA) fluorescence (up to 55%). Postoperative treatment was initiated around one month after surgery (median: 31 days) following standardized protocols in 1,041/1,420 (73.3%) cases. In 830 patients (58.5%), concomitant radiochemotherapy was started according to the established standard of care. Treatment in case of progressive disease was considerably variable. 170/1,420 patients (12.0%) underwent a second surgical procedure, 467 (33.0%) received systemic treatment after progression, and 173 (12.2%) were re-irradiated.CONCLUSION: Our data illustrate and confirm nation-wide translation of effective standard of care to Austrian glioblastoma patients in the recent past. In the case of progressive disease, highly variable therapeutic approaches were used, most frequently accompanied by anti-angiogenic therapy. Long-term survival was observed in a minor proportion of mostly younger patients who typically had gross total tumor resection, a favorable postoperative ECOG score, and standard of care therapy.
AB - PURPOSE: We present results of a retrospective population-based investigation of patterns of care and outcome of glioblastoma patients in Austria.PATIENTS AND METHODS: In this nation-wide cooperative project, all Austrian glioblastoma patients newly diagnosed between 2014 and 2018 and registered in the ABTR-SANOnet database were included. Histological typing used criteria of the WHO classification of CNS tumors, 4th edition 2016. Patterns of care were assessed, and all patients were followed until the end of 2019.RESULTS: 1,420 adult glioblastoma cases were identified. 813 (57.3%) patients were male and 607 (42.7%) female. Median age at diagnosis was 64 years (range: 18-88). Median overall survival (OS) was 11.6 months in the total cohort and 10.9 months in patients with proven IDH-wildtype. Median OS in the patient group ≤ 65 years receiving postoperative standard of care therapy was 16.1 months. In the patient group > 65 years with postoperative therapy, median OS was 11.2 months. Follow-up ≥ 5 years identified 13/264 (4.9%) long-term survivors. Brain tumor surgery frequently was assisted by 5-aminolevulinic acid (5-ALA) fluorescence (up to 55%). Postoperative treatment was initiated around one month after surgery (median: 31 days) following standardized protocols in 1,041/1,420 (73.3%) cases. In 830 patients (58.5%), concomitant radiochemotherapy was started according to the established standard of care. Treatment in case of progressive disease was considerably variable. 170/1,420 patients (12.0%) underwent a second surgical procedure, 467 (33.0%) received systemic treatment after progression, and 173 (12.2%) were re-irradiated.CONCLUSION: Our data illustrate and confirm nation-wide translation of effective standard of care to Austrian glioblastoma patients in the recent past. In the case of progressive disease, highly variable therapeutic approaches were used, most frequently accompanied by anti-angiogenic therapy. Long-term survival was observed in a minor proportion of mostly younger patients who typically had gross total tumor resection, a favorable postoperative ECOG score, and standard of care therapy.
KW - Humans
KW - Male
KW - Female
KW - Middle Aged
KW - Aged
KW - Glioblastoma/therapy
KW - Adult
KW - Austria/epidemiology
KW - Retrospective Studies
KW - Adolescent
KW - Brain Neoplasms/therapy
KW - Aged, 80 and over
KW - Young Adult
KW - Survival Rate
KW - Follow-Up Studies
KW - Combined Modality Therapy
KW - Prognosis
KW - Treatment Outcome
UR - http://www.scopus.com/inward/record.url?scp=85202198837&partnerID=8YFLogxK
U2 - 10.1007/s11060-024-04808-x
DO - 10.1007/s11060-024-04808-x
M3 - Journal article
C2 - 39192069
SN - 0167-594X
VL - 170
SP - 407
EP - 418
JO - Journal of Neuro-Oncology
JF - Journal of Neuro-Oncology
IS - 2
ER -